Dr Reddy's Laboratories
DRREDDYNSE

Dr Reddy's Laboratories

₹1,322.90-6.90 (0.52%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
F&O

Performance

Today’s low
1,313.60
Today’s high
1,340.30
52 week low
1,129.40
52 week high
1,379.70
Open price
1,327.00
Previous close
1,329.80
Live volume
12,27,007
Lower circuit
1,190.70
Upper circuit
1,455.10

Fundamentals

Market Cap
₹1,10,421Cr
ROE
16.03%
P/E Ratio(TTM)
19.99
EPS(TTM)
66.17
P/B Ratio
3.07
Dividend Yield
0.60%
Industry P/E
33.38
Book Value
431.48
Debt to Equity
0.16
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹9,022
-1.42%
Profit (Cr)
₹1,190
-11.01%
02.5k5k7.5k10k
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Revenue growthValue
1Y (TTM)+6%
3Y CAGR+15%
Profit growthValue
1Y (TTM)-15%
3Y CAGR+38%

About

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, driven by the core purpose of 'Good Health Can't Wait'. The company's vision is to accelerate access to affordable and innovative medicines, aiming to serve 1.5 billion patients by the year 2030. Its business portfolio includes Active Pharmaceutical Ingredients (APIs), generic drugs, biosimilars, over-the-counter products, and custom pharmaceutical services. The company follows a dual-track approach, which involves strengthening its core business while also building new value by investing in future growth areas. Its primary markets include the USA, India, Russia & CIS, China, Brazil, and Europe, addressing key health needs in these regions. Through its extensive network and diverse workforce, the company has established a global presence, enabling it to serve patients in 83 countries worldwide.;
CEO/MD
Erez Israeli
Founded in
1984
NSE symbol
DRREDDY

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Foreign Institutions
33.10%
Promoters
26.63%
Other Domestic Institutions
17.52%
Mutual Funds
13.19%
Retail And Others
9.55%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹1,808.30
+29.60 (1.66%)
L
    H
    4,33,847.7539.615.58
    ₹4,185.10
    -46.40 (1.10%)
    L
      H
      1,41,859.4162.4416.79
      CiplaCIPLA
      ₹1,309.60
      -8.00 (0.61%)
      L
        H
        1,05,811.4523.343.21
        LupinLUPIN
        ₹2,305.20
        -6.20 (0.27%)
        L
          H
          1,05,320.3522.565.36
          Livesquawk
          Morgan Stanley retains equal-weight on Dr. Reddy's with ₹1,259 target price. Health Canada’s semaglutide approval boosts GLP-1 portfolio; $200mn FY27 revenue potential.
          Livesquawk
          Dr. Reddy's anticipates increased competition for semaglutide in the Canadian market. Market dynamics may shift due to more entrants and rising pricing pressure.
          Livesquawk
          Dr. Reddy's secures Health Canada approval for generic semaglutide injection. This approval makes Dr. Reddy's the first to market and distribute it in Canada.
          Livesquawk
          Delhi HC warns Dr. Reddy's over 'Olymviq' trademark issue, asks compliance details. HC ordered transition from 'Olymviq' to 'Olymra' for weight-loss drug since March 30.
          Livesquawk
          BofA raises Dr. Reddy's Laboratories target to ₹1,540, citing semaglutide catalyst and diversified earnings. Resilience to geopolitical risks and cost levers expected to sustain margins above 20% despite revenue delays.
          2026
          12
          May
          Quarterly & Annual Result
          Upcoming
          Release date
          21
          Jan
          Quarterly Result
          Release date
          2025
          24
          Oct
          Quarterly Result
          Release date
          23
          Jul
          Quarterly Result
          Release date

          10
          Jul
          Dividend
          Ex date
          ₹8.00
          per share

          For each share you hold, you will receive ₹8.00
          Dividend amount₹8.00 per share
          Dividend TypeFinal
          Ex Date10 Jul ‘25
          Record Date10 Jul ‘25
          Announcement date9 May ‘25

          9
          May
          Dividend
          Announced
          ₹8.00
          per share

          For each share you hold, you will receive ₹8.00
          Dividend amount₹8.00 per share
          Dividend TypeFinal
          Ex Date10 Jul ‘25
          Record Date10 Jul ‘25
          Announcement date9 May ‘25
          2024

          28
          Oct
          Split
          Ex date
          1:5
          Ratio

          For each share you hold, you will receive 5 shares with face value of ₹1.0 each
          Split Ratio1:5
          Ex date28 Oct ‘24
          Record date28 Oct ‘24
          Announcement date27 Jul ‘24

          27
          Jul
          Split
          Announced
          1:5
          Ratio

          For each share you hold, you will receive 5 shares with face value of ₹1.0 each
          Split Ratio1:5
          Ex date28 Oct ‘24
          Record date28 Oct ‘24
          Announcement date27 Jul ‘24

          16
          Jul
          Dividend
          Ex date
          ₹40.00
          per share

          For each share you hold, you will receive ₹40.00
          Dividend amount₹40.00 per share
          Dividend TypeFinal
          Ex Date16 Jul ‘24
          Record Date17 Jul ‘24
          Announcement date7 May ‘24

          7
          May
          Dividend
          Announced
          ₹40.00
          per share

          For each share you hold, you will receive ₹40.00
          Dividend amount₹40.00 per share
          Dividend TypeFinal
          Ex Date16 Jul ‘24
          Record Date17 Jul ‘24
          Announcement date7 May ‘24
          Events calendar
          View upcoming events in other stocks